Journal
CURRENT CLINICAL PHARMACOLOGY
Volume 5, Issue 3, Pages 166-177Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157488410791498716
Keywords
Targeted therapy; breast cancer; lung cancer; colorectal cancer; resistance; therapy individualization
Categories
Ask authors/readers for more resources
Important advances have been achieved with molecular targeted agents in clinical oncology. Breast, colon, and lung cancer, are now commonly treated with a combination of chemotherapy and targeted agents. In this article the authors discuss the limitations of targeted therapy development, failures of previous studies, and possible strategies for an intelligent drug development. Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on K-RAS status are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available